<DOC>
	<DOC>NCT00779922</DOC>
	<brief_summary>The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population. and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.</brief_summary>
	<brief_title>Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Documented diagnosis of relapsed or refractory multiple myeloma (MM). Age &gt; 18 years at the time of signing the informed consent form Stable renal function Documented amyloidosis Any prior use of Revlimid ® Any contraindication to Revlimid ® and especially: Lack of acceptable method of birth control for female of childbearing potential (FCPB) Men who don't agree to use condom during the study and 4 weeks after the last study drug intake if their partner is a FCPB. Pregnant or breast feeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>impaired renal function</keyword>
</DOC>